Ghent University Academic Bibliography

Show Sort by

Your filters: cql: parent exact "ONCOLOGY"

Mark
A randomized phase II study comparing two schedules of the 21-day regimen of gemcitabine and carboplatin in advanced non-small cell lung cancer

Veerle Surmont (UGent) , JGJV Aerts, RJ van Klaveren, K Tournoy, KY Tan, RM Vernhout, PIM Schmitz, C Legrand, HC Hoogsteden and JP van Meerbeeck

(2010) ONCOLOGY. 78(3-4). p.267-270
Mark
- journalArticle
- A1
Independent risk factors for anemia in cancer patients receiving chemotherapy: Results from the European Cancer Anaemia Survey

PJ BARRETT-LEE, H LUDWIG, G BIRGEGARD, C BOKEMEYER, P GASCON, PA KOSMIDIS, M KRZAKOWSKI, JWR NORTIER, G KONGABLE, M SCHNEIDER, et al.

(2006) ONCOLOGY. 70(1). p.34-48
Mark
- journalArticle
- A1
Cancer-related anemia: Pathogenesis, prevalence and treatment

G BIRGEGARD, MS AAPRO, C BOKEMEYER, M DICATO, P DRINGS, J HORNEDO, M KRZAKOWSKI, H LUDWIG, S PECORELLI, H SCHMOLL, et al.

(2005) ONCOLOGY. 68. p.3-11
Mark
- journalArticle
- A1
Cancer-related anemia: Biological findings, clinical implications and impact on quality of life

JU BLOHMER, J DUNST, L HARRISON, P JOHNSTON, D KHAYAT, H LUDWIG, M O'BRIEN, Simon Van Belle (UGent) and P VAUPEL

(2005) ONCOLOGY. 68. p.12-21
Mark
- journalArticle
- A1
Raltitrexed plus Gemcitabine (TOMGEM) in advanced pancreatic cancer - Results of a Belgian Multicentre Phase II Study

JL VAN LAETHEM, P VAN MAELE, C VERSLYPEC, M POLUS, A DEMOLS, G HOUBIERS, P CAENEPEEL, A LELEUX, RR VERMAUT, E VAN CUTSEM, et al.

(2004) ONCOLOGY. 67(5-6). p.338-343
Mark
- journalArticle
- A1
Ondansetron suppository: A randomised, double-blind, double-dummy, parallel-group comparison with oral ondansetron for the prevention of cyclophosphamide-induced emesis and nausea.

NGP DAVIDSON, W PASKA, S VANBELLE, L GOEDHALS, B MCQUADE and J MCRAE

(1997) ONCOLOGY. 54(5). p.380-386
Mark
- journalArticle
- A1
Effect of anticancer agents on invasion of mouse fibrosarcoma cells in vitro.

G STORME and Marcus Mareel (UGent)

(1981) ONCOLOGY. 38(3). p.182-186
Mark
- journalArticle
- A1
Methyl[5-(2-thienylcarbonyl)-1H-Benzimidazole-2-yl] Carbamate (R17934), a synthetic microtubule inhibitor, prevents malignant invasion in vitro.

Marcus Mareel (UGent) and M DE BRABANDER

(1978) ONCOLOGY. 35(1).
Mark
- journalArticle
- A1
Invasion of malignant cells into 51Cr-labeled host tissues in organotypical culture

Marcus Mareel (UGent) , Georges De Bruyne (UGent) and Leo De Ridder (UGent)

(1977) ONCOLOGY. 34(1). p.6-9

Academic Bibliography

A randomized phase II study comparing two schedules of the 21-day regimen of gemcitabine and carboplatin in advanced non-small cell lung cancer

Independent risk factors for anemia in cancer patients receiving chemotherapy: Results from the European Cancer Anaemia Survey

Cancer-related anemia: Pathogenesis, prevalence and treatment

Cancer-related anemia: Biological findings, clinical implications and impact on quality of life

Raltitrexed plus Gemcitabine (TOMGEM) in advanced pancreatic cancer - Results of a Belgian Multicentre Phase II Study

Ondansetron suppository: A randomised, double-blind, double-dummy, parallel-group comparison with oral ondansetron for the prevention of cyclophosphamide-induced emesis and nausea.

Effect of anticancer agents on invasion of mouse fibrosarcoma cells in vitro.

Methyl[5-(2-thienylcarbonyl)-1H-Benzimidazole-2-yl] Carbamate (R17934), a synthetic microtubule inhibitor, prevents malignant invasion in vitro.

Invasion of malignant cells into 51Cr-labeled host tissues in organotypical culture

Contents

Support

Contact